Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Repligen Corp

+ Add to Watchlist

RGEN:US

30.5700 USD 2.0000 7.00%

As of 20:10:00 ET on 03/27/2015.

Snapshot for Repligen Corp (RGEN)

Open: 28.6000 Day's Range: 28.2900 - 30.8200 Volume: 326,720
Previous Close: 28.5700 52wk Range: 12.3100 - 34.1500 1-Yr Rtn: +144.95%

Stock Chart for RGEN

No chart data available.
  • RGEN:US 30.5700
  • 1D
  • 1M
  • 1Y
28.5700
Interactive RGEN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for RGEN

Current P/E Ratio (ttm) 106.6610
Estimated P/E(12/2015) 102.9293
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) 0.2866
Est. EPS (USD) (12/2015) 0.2970
Est. PEG Ratio -
Market Cap (M USD) 1,002.02
Shares Outstanding (M) 32.78
30 Day Average Volume 438,518
Price/Book (mrq) 8.9671
Price/Sale (ttm) 15.5859
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/08/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for RGEN

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for RGEN

Repligen Corporation is a biotechnology company. The Company develops therapeutics for the treatment of diseases of the central nervous system. Repligen owns owns intellectual property on monoclonal antibody and antibody fusion products.

Walter C HerlihyPresident/CEO/TreasurerTony J HuntChief Operating Officer
Jon K SnodgresChief Financial OfficerJames R RuscheSenior VP:Research & Dev
More Company Profile & Key Executives for RGEN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil